Abstract
Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Xinzhe Zhang, Gaojie Wang, Baodong He, Jiao Gao, Wenying Qiu
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
ror
Confidence 99%
pubmed
Confidence 98%
europepmc
Confidence 96%
unpaywall
Confidence 95%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Amyotrophic lateral sclerosis
10.1016/s0140-6736(22)01272-7 · 2022
Advances in molecular pathology, diagnosis, and treatment of amyotrophic lateral sclerosis
10.1136/bmj-2023-075037 · 2023
New developments and opportunities in drugs being trialed for amyotrophic lateral sclerosis from 2020 to 2022
10.3389/fphar.2022.1054006 · 2022
Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: A retrospective analysis of data from a dose-ranging study
10.1016/s1474-4422(18)30054-1 · 2018
Safety and effectiveness of long-term intravenous administration of edaravone for treatment of patients with amyotrophic lateral sclerosis
10.1001/jamaneurol.2021.4893 · 2022
Neuroinflammation in amyotrophic lateral sclerosis: Role of glial activation in motor neuron disease
10.1016/s1474-4422(11)70015-1 · 2011
Immune dysregulation in amyotrophic lateral sclerosis: Mechanisms and emerging therapies
10.1016/s1474-4422(18)30394-6 · 2019
Neuronal STING activation in amyotrophic lateral sclerosis and frontotemporal dementia
10.1007/s00401-024-02688-z · 2024
cGAS-STING drives ageing-related inflammation and neurodegeneration
10.1038/s41586-023-06373-1 · 2023
TDP-43 and inflammation: Implications for amyotrophic lateral sclerosis and frontotemporal dementia
10.3390/ijms22157781 · 2021
TDP-43 triggers mitochondrial DNA release via mPTP to activate cGAS/STING in ALS
10.1016/j.cell.2020.09.020 · 2020
cGAS and DDX41-STING mediated intrinsic immunity spreads intercellularly to promote neuroinflammation in SOD1 ALS model
10.1016/j.isci.2022.104404 · 2022
The cGAS-STING pathway drives neuroinflammation and neurodegeneration via cellular and molecular mechanisms in neurodegenerative diseases
10.1016/j.nbd.2024.106710 · 2024
STING signaling in the brain: Molecular threats, signaling activities, and therapeutic challenges
10.1016/j.neuron.2023.10.014 · 2024
Bruton's tyrosine kinase and phospholipase Cγ2 mediate chemokine-controlled B cell migration and homing
10.1016/j.immuni.2006.11.012 · 2007
Myd88 adapter-like (Mal) is phosphorylated by Bruton's tyrosine kinase during TLR2 and TLR4 signal transduction
10.1074/jbc.m508892200 · 2006
The B cell antigen receptor controls integrin activity through Btk and PLCγ2
10.1084/jem.20011866 · 2003
Bruton's tyrosine kinase is a toll/interleukin-1 receptor domain-binding protein that participates in nuclear factor κB activation by toll-like receptor 4
10.1074/jbc.m301484200 · 2003
Treatment of patients with relapsed or refractory mantle–cell lymphoma with zanubrutinib, a selective inhibitor of Bruton's tyrosine kinase
10.1158/1078-0432.ccr-19-3703 · 2020
Bruton's tyrosine kinase inhibitors: Recent updates
10.3390/ijms25042208 · 2024
The MAGNOLIA trial: Zanubrutinib, a next-generation Bruton tyrosine kinase inhibitor, demonstrates safety and efficacy in relapsed/refractory marginal zone lymphoma
10.1158/1078-0432.ccr-21-1704 · 2021
BTK regulates microglial function and neuroinflammation in human stem cell models and mouse models of multiple sclerosis
10.1038/s41467-024-54430-8 · 2024
Expression of Bruton´s tyrosine kinase in different type of brain lesions of multiple sclerosis patients and during experimental demyelination
10.3389/fimmu.2023.1264128 · 2023
Inhibition of Bruton's tyrosine kinase modulates microglial phagocytosis: Therapeutic implications for Alzheimer's disease
10.1007/s11481-019-09839-0 · 2019
Bruton's tyrosine kinase inhibition ameliorated neuroinflammation during chronic white matter ischemia
10.1186/s12974-024-03187-4 · 2024
BTK inhibition limits microglia-perpetuated CNS inflammation and promotes myelin repair
10.1007/s00401-024-02730-0 · 2024
Standardized operational protocol for the China Human Brain Bank Consortium (2nd edition)
2024
Standardized operational protocol for human brain banking in China
10.1007/s12264-018-0306-7 · 2019
Large-scale differentiation of iPSC-derived motor neurons from ALS and control subjects
10.1016/j.neuron.2023.01.010 · 2023
Inhibition of Bruton's tyrosine kinase restricts neuroinflammation following intracerebral hemorrhage
10.7150/thno.101024 · 2025
Fenebrutinib, a Bruton's tyrosine kinase inhibitor, blocks distinct human microglial signaling pathways
10.1186/s12974-024-03267-5 · 2024
Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS)
10.1371/journal.pone.0009872 · 2010
Phosphatase and tensin homologue/protein kinase B pathway linked to motor neuron survival in human superoxide dismutase 1-related amyotrophic lateral sclerosis
10.1093/brain/awq345 · 2011
Sporadic ALS has compartment-specific aberrant exon splicing and altered cell-matrix adhesion biology
10.1093/hmg/ddp498 · 2010
Loss of nuclear TDP-43 in amyotrophic lateral sclerosis (ALS) causes altered expression of splicing machinery and widespread dysregulation of RNA splicing in motor neurones
10.1111/nan.12148 · 2014
Bruton's tyrosine kinase phosphorylates DDX41 and activates its binding of dsDNA and STING to initiate type 1 interferon response
10.1016/j.celrep.2015.01.039 · 2015
Human prefrontal cortex gene regulatory dynamics from gestation to adulthood at single-cell resolution
10.1016/j.cell.2022.09.039 · 2022
Microglia in neurodegeneration
10.1038/s41593-018-0242-x · 2018
Single-cell RNA sequencing of microglia throughout the mouse lifespan and in the injured brain reveals complex cell-state changes
10.1016/j.immuni.2018.11.004 · 2019
A map of transcriptional heterogeneity and regulatory variation in human microglia
10.1038/s41588-021-00875-2 · 2021
From development to clinical success: The journey of established and next-generation BTK inhibitors
10.1007/s10637-025-01513-y · doi-reference
Phase 1 study of the selective BTK inhibitor zanubrutinib in B-cell malignancies and safety and efficacy evaluation in CLL
10.1182/blood.2019001160 · doi-reference
Onset and progression in inherited ALS determined by motor neurons and microglia
10.1126/science.1123511 · doi-reference
Cell-autonomous immune dysfunction driven by disrupted autophagy in C9orf72-ALS iPSC-derived microglia contributes to neurodegeneration
10.1126/sciadv.abq0651 · doi-reference
Bruton's tyrosine kinase together with PI3-kinase are part of toll-like receptor 2 multiprotein complex and mediate LTA induced toll-like receptor 2 responses in macrophages
10.1016/j.cellsig.2006.08.013 · doi-reference
TBK1 directly engages Akt/PKB survival signaling to support oncogenic transformation
10.1016/j.molcel.2011.01.019 · doi-reference
Dysregulated phosphoinositide 3-kinase signaling in microglia: Shaping chronic neuroinflammation
10.1186/s12974-021-02325-6 · doi-reference
The importance of phosphoinositide 3-kinase in neuroinflammation
10.3390/ijms252111638 · doi-reference
Resistance to BTK inhibition by ibrutinib can be overcome by preventing FOXO3a nuclear export and PI3K/AKT activation in B-cell lymphoid malignancies
10.1038/s41419-019-2158-0 · doi-reference
Single-cell dissection of the human motor and prefrontal cortices in ALS and FTLD
10.1016/j.cell.2024.02.031 · doi-reference
TBK1 and IKKε act redundantly to mediate STING-induced NF-κB responses in myeloid cells
10.1016/j.celrep.2020.03.056 · doi-reference